Skip to main content
Clinical Trials/NCT00742274
NCT00742274
Completed
Not Applicable

A Randomized European Study Comparing Endoluminal Stent Grafting and Best Medical Therapy (BMT) to BMT Alone in the Treatment of Acute Uncomplicated Type B Aortic Dissection

W.L.Gore & Associates0 sites61 target enrollmentAugust 2008
ConditionsAortic Diseases

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Aortic Diseases
Sponsor
W.L.Gore & Associates
Enrollment
61
Primary Endpoint
Composite of Partial or No False Lumen Thrombosis, Aortic Rupture, and Aortic Dilatation
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study is to compare endoluminal stent grafting with the GORE TAG device and Best Medical Therapy (BMT) to BMT alone in the treatment of acute uncomplicated type B aortic dissections.

Detailed Description

Dissection of the aorta is a medical emergency requiring immediate surgery. Type B dissections are typically treated with surgery or endoluminal therapy when complications such as uncontrollable pain, organ ischemia, or aortic rupture are present. However, the treatment of patients with uncomplicated, acute type B dissections is controversial. Best medical therapy (BMT) is the standard of care in these cases since surgical repair offers no additional survival advantage. However, Endoluminal stent graft therapy with the GORE TAG Thoracic Endoprosthesis (GORE TAG device) may offer distinct advantages as an adjunct to medical therapy for uncomplicated acute type B dissection. The goal of endoluminal stent grafting is to cover the primary entry tear of the dissection to isolate the false lumen from blood flow and induce aortic remodeling.

Registry
clinicaltrials.gov
Start Date
August 2008
End Date
October 2013
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
W.L.Gore & Associates
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Presence of acute uncomplicated type B aortic dissection
  • Able to tolerate endotracheal intubation and general anesthesia
  • Maximum transverse diameter of the descending thoracic aorta \< 55 mm and absence of descending thoracic aortic aneurysm, regardless of etiology.
  • Arterial anatomy is appropriate for stent graft therapy

Exclusion Criteria

  • ASA classification = V
  • Severe renal insufficiency defined as SVS risk renal status = 3
  • Severe respiratory insufficiency defined as SVS risk pulmonary status = 3
  • Presence of connective tissue disease
  • Active infection or active vasculitides
  • Positive pregnancy test
  • Participation in another medical research study within 3 months of study enrollment
  • Myocardial infarction or cerebrovascular accident within 6 weeks prior to study enrollment
  • Planned concomitant surgical procedures (other than left subclavian artery transposition or bypass), or major surgery within 30 days of study enrollment
  • History of drug abuse

Outcomes

Primary Outcomes

Composite of Partial or No False Lumen Thrombosis, Aortic Rupture, and Aortic Dilatation

Time Frame: 1 year

Subjects with any of the following met this composite outcome: * partial/no false lumen thrombosis * aortic rupture * aortic dilatation * lack of 1 year imaging (no image, incomplete image missing primary endpoint measurements, unevaluable image)

Similar Trials